194 related articles for article (PubMed ID: 21148040)
1. Successful colon cancer eradication after chemoimmunotherapy is associated with profound phenotypic change of intratumoral myeloid cells.
Medina-Echeverz J; Fioravanti J; Zabala M; Ardaiz N; Prieto J; Berraondo P
J Immunol; 2011 Jan; 186(2):807-15. PubMed ID: 21148040
[TBL] [Abstract][Full Text] [Related]
2. Skewing the Th cell phenotype toward Th1 alters the maturation of tumor-infiltrating mononuclear phagocytes.
Nonaka K; Saio M; Suwa T; Frey AB; Umemura N; Imai H; Ouyang GF; Osada S; Balazs M; Adany R; Kawaguchi Y; Yoshida K; Takami T
J Leukoc Biol; 2008 Sep; 84(3):679-88. PubMed ID: 18566103
[TBL] [Abstract][Full Text] [Related]
3. Cyclophosphamide-induced myeloid-derived suppressor cell population is immunosuppressive but not identical to myeloid-derived suppressor cells induced by growing TC-1 tumors.
Mikyšková R; Indrová M; Polláková V; Bieblová J; Símová J; Reiniš M
J Immunother; 2012 Jun; 35(5):374-84. PubMed ID: 22576342
[TBL] [Abstract][Full Text] [Related]
4. In vivo elimination of CD25+ regulatory T cells leads to tumor rejection of B16F10 melanoma, when combined with interleukin-12 gene transfer.
Nagai H; Horikawa T; Hara I; Fukunaga A; Oniki S; Oka M; Nishigori C; Ichihashi M
Exp Dermatol; 2004 Oct; 13(10):613-20. PubMed ID: 15447721
[TBL] [Abstract][Full Text] [Related]
5. Depletion of regulatory T cells facilitates growth of established tumors: a mechanism involving the regulation of myeloid-derived suppressor cells by lipoxin A4.
Zhang B; Jia H; Liu J; Yang Z; Jiang T; Tang K; Li D; Huang C; Ma J; Shen GX; Ye D; Huang B
J Immunol; 2010 Dec; 185(12):7199-206. PubMed ID: 21068404
[TBL] [Abstract][Full Text] [Related]
6. Intratumoral interleukin-21 increases antitumor immunity, tumor-infiltrating CD8+ T-cell density and activity, and enlarges draining lymph nodes.
Søndergaard H; Galsgaard ED; Bartholomaeussen M; Straten PT; Odum N; Skak K
J Immunother; 2010 Apr; 33(3):236-49. PubMed ID: 20445344
[TBL] [Abstract][Full Text] [Related]
7. Two distinct mechanisms of augmented antitumor activity by modulation of immunostimulatory/inhibitory signals.
Mitsui J; Nishikawa H; Muraoka D; Wang L; Noguchi T; Sato E; Kondo S; Allison JP; Sakaguchi S; Old LJ; Kato T; Shiku H
Clin Cancer Res; 2010 May; 16(10):2781-91. PubMed ID: 20460483
[TBL] [Abstract][Full Text] [Related]
8. The requirement of multimodal therapy (vaccine, local tumor radiation, and reduction of suppressor cells) to eliminate established tumors.
Kudo-Saito C; Schlom J; Camphausen K; Coleman CN; Hodge JW
Clin Cancer Res; 2005 Jun; 11(12):4533-44. PubMed ID: 15958639
[TBL] [Abstract][Full Text] [Related]
9. Synergistic antitumor effects of regulatory T cell blockade combined with pemetrexed in murine malignant mesothelioma.
Anraku M; Tagawa T; Wu L; Yun Z; Keshavjee S; Zhang L; Johnston MR; de Perrot M
J Immunol; 2010 Jul; 185(2):956-66. PubMed ID: 20548032
[TBL] [Abstract][Full Text] [Related]
10. Successful adoptive immunotherapy of murine poorly immunogenic tumor with specific effector cells generated from gene-modified tumor-primed lymph node cells.
Tanaka H; Yoshizawa H; Yamaguchi Y; Ito K; Kagamu H; Suzuki E; Gejyo F; Hamada H; Arakawa M
J Immunol; 1999 Mar; 162(6):3574-82. PubMed ID: 10092816
[TBL] [Abstract][Full Text] [Related]
11. The systemic administration of Ig-4-1BB ligand in combination with IL-12 gene transfer eradicates hepatic colon carcinoma.
Xu DP; Sauter BV; Huang TG; Meseck M; Woo SL; Chen SH
Gene Ther; 2005 Oct; 12(20):1526-33. PubMed ID: 15973445
[TBL] [Abstract][Full Text] [Related]
12. Depleting intratumoral CD4+CD25+ regulatory T cells via FasL protein transfer enhances the therapeutic efficacy of adoptive T cell transfer.
Chen A; Liu S; Park D; Kang Y; Zheng G
Cancer Res; 2007 Feb; 67(3):1291-8. PubMed ID: 17283166
[TBL] [Abstract][Full Text] [Related]
13. CD4 T cells inhibit in vivo the CD8-mediated immune response against murine colon carcinoma cells transduced with interleukin-12 genes.
Martinotti A; Stoppacciaro A; Vagliani M; Melani C; Spreafico F; Wysocka M; Parmiani G; Trinchieri G; Colombo MP
Eur J Immunol; 1995 Jan; 25(1):137-46. PubMed ID: 7843224
[TBL] [Abstract][Full Text] [Related]
14. Early exposure of high-dose interleukin-4 to tumor stroma reverses myeloid cell-mediated T-cell suppression.
Jiang J; Wang Z; Li Z; Zhang J; Wang C; Xu X; Qin Z
Gene Ther; 2010 Aug; 17(8):991-9. PubMed ID: 20410929
[TBL] [Abstract][Full Text] [Related]
15. Tumor regression by anti-CD40 and interleukin-2: role of CD40 in hematopoietic cells and organ-specific effects.
Welniak LA; Shorts L; Subleski J; Blazar BR; Wiltrout RH; Murphy WJ
Biol Blood Marrow Transplant; 2004 Aug; 10(8):534-9. PubMed ID: 15282531
[TBL] [Abstract][Full Text] [Related]
16. Multiple roles of interferon-gamma in the mediation of interleukin 12-induced tumor regression.
Ogawa M; Yu WG; Umehara K; Iwasaki M; Wijesuriya R; Tsujimura T; Kubo T; Fujiwara H; Hamaoka T
Cancer Res; 1998 Jun; 58(11):2426-32. PubMed ID: 9622084
[TBL] [Abstract][Full Text] [Related]
17. Intratumoral delivery of IL-12 gene by polyvinyl polymeric vector system to murine renal and colon carcinoma results in potent antitumor immunity.
Mendiratta SK; Quezada A; Matar M; Wang J; Hebel HL; Long S; Nordstrom JL; Pericle F
Gene Ther; 1999 May; 6(5):833-9. PubMed ID: 10505108
[TBL] [Abstract][Full Text] [Related]
18. In vivo gene transfer of CD40 ligand into colon cancer cells induces local production of cytokines and chemokines, tumor eradication and protective antitumor immunity.
Sun Y; Peng D; Lecanda J; Schmitz V; Barajas M; Qian C; Prieto J
Gene Ther; 2000 Sep; 7(17):1467-76. PubMed ID: 11001366
[TBL] [Abstract][Full Text] [Related]
19. Cyclophosphamide and IL-12-transduced DCs enhance the antitumor activity of tumor antigen-stimulated DCs and reduce Tregs and MDSCs number.
Rossowska J; Pajtasz-Piasecka E; Anger N; Wojas-Turek J; Kicielińska J; Piasecki E; Duś D
J Immunother; 2014; 37(9):427-39. PubMed ID: 25304726
[TBL] [Abstract][Full Text] [Related]
20. Distinct responses of two hepatocellular carcinoma cell lines of a similar origin to immunotherapies targeting regulatory or effector T cells.
Nagayama Y; Hase W; Motoyoshi Y; Saitoh O; Sogawa R; Nakao K
Oncol Rep; 2007 May; 17(5):1269-73. PubMed ID: 17390075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]